Todas las investigaciones
ReclutamientoFarmacología Humana (Fase I) - Primera administración en humanosIntervencionista

PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients with solid tumors – a Phase 0 basket trial

This clinical trial is testing two new imaging substances, known as Vartumabs, in adults with solid tumours. A PET scan is a common hospital scan that produces detailed pictures of the inside of the body using a tiny amount of a tracking dye. In this trial, researchers are giving a very small dose of a new tracer to see if it sticks to tumour cells and makes them show up clearly on the scan. This is a 'Phase 0' trial, which means it uses very low doses to test how the substance behaves in the human body, rather than to treat the cancer directly. The study is open to adults aged 18 and over with solid tumours. The main aim is to check if these new tracers are safe and useful for future cancer diagnosis and monitoring.

De un vistazo

Estado
Reclutamiento
Fase
Farmacología Humana (Fase I) - Primera administración en humanos
Patrocinador
Var2 Pharmaceuticals ApS
Objetivo de inscripción
32
Inicio
24 Sep 2024

¿De qué trata este estudio?

Getting a clear picture of a tumour is essential for choosing the best cancer treatment. Doctors often use PET scans, which use a mild tracking substance injected into the bloodstream to highlight areas of disease. This trial is looking at two new experimental tracers called Vartumabs (F8scFv and C9scFv) to see if they can improve how solid tumours are visualised.

Vartumabs are made from small fragments of antibodies, which are proteins designed to search for and attach to specific markers on cancer cells. When these fragments carry a tiny, safe amount of radiation, they act like a beacon. If they attach to tumour cells, the PET camera can detect them, showing doctors exactly where the cancer is.

This study is called a Phase 0 'basket trial'. The term 'basket' means it includes patients with different types of solid tumours—such as lung, bowel, or breast cancer—rather than just one type. Because it is Phase 0, the amount of tracer given is extremely small. The study is not designed to shrink or cure the cancer, but to test how well the imaging works. The results could help scientists develop more accurate scanning tools for cancer patients in the future.

Puntos clave

  • Tests two new imaging dyes (Vartumabs) to improve cancer PET scans.
  • Open to adults aged 18 and over with solid tumours.
  • This is an imaging trial, not a cancer treatment.
  • Involves a small injection into a vein followed by a PET scan.
  • Participation is voluntary and does not replace your routine cancer care.

¿Quién puede ser elegible?

This trial is open to adults aged 18 and older who have been diagnosed with a solid tumour. A solid tumour is a cancer that forms a lump or mass in body tissues, such as the breast, bowel, or prostate, rather than a blood cancer like leukaemia.

To take part, you will need to be well enough to visit the hospital, have a small injection into a vein, and lie still inside a PET scanner for the duration of the scan. Your care team will check your overall health, including your kidney and liver function, to make sure taking part is safe for you.

You might not be able to take part if you are pregnant, planning to become pregnant, or breastfeeding. People with severe allergies to imaging dyes or certain other medical conditions may also be excluded. Your doctor can review the full checklist with you.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. I am aged 18 or over.
  2. I have been diagnosed with a solid tumour cancer.
  3. I am able to lie still in a scanner for up to an hour.
  4. I am not pregnant or breastfeeding.
  5. I am able to travel to the study hospital for scan appointments.
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

Taking part involves attending a specialist hospital or scanning centre. A doctor or nurse will place a small needle (cannula) into a vein in your arm to inject the Vartumab tracer. You will then wait for a set period while the tracer moves through your body and binds to any tumour cells.

Next, you will have a PET scan, which involves lying flat on a padded table that gently slides into a ring-shaped scanner. The scan usually takes between 30 and 60 minutes. Staff will monitor you closely during and after the scan to check for any side effects. Your total time in the study is typically short—often just one or two visits covering the screening, the scan day, and a brief follow-up check.

Riesgos y beneficios potenciales

Because this study uses tiny doses, it is not expected to shrink your tumour or treat your cancer directly. However, taking part may provide detailed scan images of your condition and could help doctors improve cancer scans for others in the future. The risks are generally low. You may experience minor bruising or discomfort from the needle in your arm. PET scans involve a small amount of radiation, similar to other standard hospital scans. Allergic reactions are rare, but the medical team will monitor you closely. Joining the study is completely voluntary, and you can withdraw at any time without it affecting your regular NHS cancer care.

Ubicaciones (1)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    Países Bajos

Preguntas comunes

Will this trial treat or cure my cancer?

No. This is an imaging study using very low doses to test a new scanning method. It is designed to take pictures of cancer, not to treat it.

What is a Phase 0 trial?

A Phase 0 trial is a very early study in humans that uses tiny, non-treatment doses to see how a new substance travels through the body and whether it reaches its target safely.

Is the radiation from the PET scan dangerous?

The scan uses a very small, carefully controlled amount of radiation, comparable to standard diagnostic tests. The study team ensures the dose is kept as low as reasonably possible.

Do I have to stop my regular cancer treatment to join?

This depends on the trial's exact schedule and your current treatment plan. Your cancer specialist will tell you whether joining fits safely alongside your current care.

¿Puedo abandonar el estudio si cambio de opinión?

Yes, you can leave the study at any point. You do not have to give a reason, and your normal medical care will continue as usual.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.